Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03790995
Other study ID # Be-RALP functioning and QoL
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 2009
Est. completion date February 2018

Study information

Verified date December 2018
Source KU Leuven
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The Be-RALP database is Belgian prospective multicenter database governed by the Belgian cancer registry. This database investigates the status after robot assisted laparoscopic prostatectomy (RALP) in prostate cancer patients. It was established by a collaboration between the Belgian association of Urology (BAU), the National Institute for Health and Disability Insurance (NIHDI) and the Belgian cancer registry.

Between 2009 and 2016, 9235 patients were included in this patient registry.

The studied outcomes covered quality of life measures as well as variables covering urinary and erectile function.


Description:

The Be-RALP database is Belgian prospective multicenter database governed by the Belgian cancer registry. This was established by a collaboration between the Belgian association of Urology (BAU), the National Institute for Health and Disability Insurance (NIHDI) and the Belgian cancer registry.

Twenty-five centres, on average 90% of all Belgian robotic centres, collected prospective data of 9235 patients from October 2009 until February 2016. These data is collected by local data managers or physicians and was required to receive reimbursion from the NIHDI for the disposables used during robot surgery. After filling in the data by the local datamanagers, the data is centralised. In Brussels the data is protected and further used by data managers and statisticians. In this system in-and output of data is strictly separated. Patient data is encoded to ensure absolute privacy. Then the data is checked upon correctness by using random checks. Data is completed where necessary.

These parameters increase the quality of data handling and database.

The final database consists of baseline pre-, per- and postoperative data as well as four standardised follow-up registrations (on 1, 3, 12 and 24 months), with follow-up data still being collected. In each follow-up registration, functional parameters and quality of life are re-assessed together with postoperative treatment status and PSA.

The Be-RALP database collected patient details of 9235 patients treated by RARP between 2009 and 2016. Patients with macro metastasis and initial PSA values higher than 100 (probable undetected micro metastasis) were excluded for this study, as well as all pT0, patients with surgery after the closing date and patients with invalid survival data. Further exclusion of patients with missing values for nerve sparing, extend of nerve sparing and risk category resulted in a group of 8306 patients.

The selected outcomes covered in the database consist of quality of life measures (European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 global, physical, emotional and cognitive) as well as variables covering urinary (Incontinence Modular Questionnaire-Urinary Incontinence: ICIQ, EORTC QLQ-PR25 urinary symptoms, incontinence aid) and erectile function (International Index of Erectile Function: IIEF, EORTC QLQ-PR25 sexual activity and sexual functioning).

A 1:1 matching between high and low-intermediate prostate cancer will be performed. Afterwards, longitudinal mixed models will quantify the relation between the explanatory variables follow-up time, risk group (high vs. low-intermediate) and postoperative treatment (postoperative radiotherapy (RT) and/or androgen deprivation therapy (ADT): yes vs. no) and the outcomes erectile- and urinary function as well as Quality of Life. All analysis will be performed using the statistical analysis software (SAS system), version 9.3.


Recruitment information / eligibility

Status Completed
Enrollment 9235
Est. completion date February 2018
Est. primary completion date February 2016
Accepts healthy volunteers No
Gender Male
Age group N/A and older
Eligibility Inclusion Criteria:

- Diagnosed with prostate cancer

- Eligible to undergo RALP

- RALP in one of the 25 participating centres

Exclusion Criteria:

- iPSA > 100

- Confirmed metastasis

- invalid survival data

- pT0

- Missing nerve sparing details

- Missing risk group

Study Design


Intervention

Procedure:
Robot assisted laparoscopic prostatectomy


Locations

Country Name City State
Belgium Algemeen Stedelijk Ziekenhuis Aalst Aalst
Belgium Onze-Lieve-Vrouwziekenhuis Aalst-Asse-Ninove Aalst
Belgium GZA ziekenhuizen - Campus Sint-Augustinus Antwerp
Belgium AZ Klina Brasschaat
Belgium AZ Sint-Jan Brugge-Oostende Brugge
Belgium AZ Sint-Lucas Brugge
Belgium CHIREC Brussels
Belgium CHU Saint-Pierre Bruxelles Brussels
Belgium Hôpital Erasme Bruxelles Brussels
Belgium Institut Jules Bordet Bruxelles Brussels
Belgium AZ Sint Blasius Dendermonde Dendermonde
Belgium AZ Jan Palfijn Gent Gent
Belgium AZ Maria Middelares Gent Gent
Belgium AZ Sint-Lucas Gent Gent
Belgium Universitair Ziekenhuis Gent Gent
Belgium AZ Groeninge Kortrijk
Belgium Universitaire ziekenhuizen Leuven Leuven
Belgium CHR de la Citadelle Liège Liège
Belgium CHU Ambroise Paré Mons Mons
Belgium AZ Damiaan Oostende
Belgium AZ Delta-Heilig Hart Ziekenhuis Roeselare-Menen Roeselare
Belgium Cliniques de l'Europe Bruxelles Uccle
Belgium AZ Jan Portaels Vilvoorde
Belgium Cliniques Universitaires de Mont-Godinne Yvoir
Belgium AZ Sint-Elisabeth Zottegem Zottegem

Sponsors (2)

Lead Sponsor Collaborator
KU Leuven Belgian Cancer Registry

Country where clinical trial is conducted

Belgium, 

References & Publications (2)

Albisinni S, Joniau S, Quackels T, De Coster G, Dekuyper P, Van Cleynenbreugel B, Van Damme N, Van Eycken E, Ameye F, Roumeguère T; Be-RALP Registry (Belgian Robotic-Assisted Laparoscopic Prostatectomy Registry). Current trends in patient enrollment for robotic-assisted laparoscopic prostatectomy in Belgium. Cancer. 2017 Nov 1;123(21):4139-4146. doi: 10.1002/cncr.30874. Epub 2017 Jul 25. — View Citation

Lorenzo,Tosco, Greet De Coster, Thierry Roumeguère et all, the Be RALP the Belgian RALP consortium. Development and External Validation of Nomograms To Predict Adverse Pathological Characteristics After Robotic Prostatectomy: Results of a Prospective, Multi-institutional, Nationwide series. September 2018, Pages 338-345

Outcome

Type Measure Description Time frame Safety issue
Primary Global quality of life EORTC C30 global quality of life, questionnaire Longitudinal modelling over 24 months
Primary Emotional quality of life EORTC C30 emotional quality of life, questionnaire Longitudinal modelling over 24 months
Primary physical quality of life EORTC C30 physical quality of life, questionnaire Longitudinal modelling over 24 months
Primary Cognitive quality of life EORTC C30 cognitive quality of life, questionnaire Longitudinal modelling over 24 months
Primary Erectile function - IIEF 5 International Index of Erectile Function (IIEF-5), questionnaire Longitudinal modelling over 24 months
Primary Erectile function - sexual activity EORTC PR25 sexual activity, questionnaire Longitudinal modelling over 24 months
Primary Erectile function - sexual functioning EORTC PR25 sexual functioning, questionnaire Longitudinal modelling over 24 months
Primary Urinary function - Incontinence aid EORTC PR25 incontinence aid, questionnaire Longitudinal modelling over 24 months
Primary Urinary function - urinary symptoms EORTC PR25 urinary symptoms, questionnaire Longitudinal modelling over 24 months
Primary Urinary function - ICIQ International Consultation on Incontinence Questionnaire Longitudinal modelling over 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A